Showing results (1981-1990 of 2,107) with videos related to
Sort By:
Pageof 211
CNS Drugs|February 14, 2022
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure MedicationAdam Strzelczyk, Susanne Schubert-BastCNS Drugs|February 14, 2022
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 StudyZhen Luo, Hong Tu, Xiang Zhang, et al.CNS Drugs|May 17, 2019
Potential Role of Vitamin D for the Management of Depression and AnxietyGleicilaine A S Casseb, Manuella P Kaster, Ana Lúcia S RodriguesCNS Drugs|April 13, 2019
The Potential of Cannabinoid-Based Treatments in Tourette SyndromeBekir B Artukoglu, Michael H BlochCNS Drugs|April 13, 2019
Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseFaizan Mazhar, Marco Pozzi, Marta Gentili, et al.CNS Drugs|February 3, 2022
Alternative Routes of Administration of ClozapineSiobhan Gee, David TaylorCNS Drugs|April 5, 2022
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON TrialThomas Roth, Yves Dauvilliers, Michael J Thorpy, et al.CNS Drugs|March 22, 2022
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric DisordersRichard C J Bradlow, Michael Berk, Peter W Kalivas, et al.CNS Drugs|July 11, 2019
Drug Treatment of Clinically Isolated SyndromeMoritz Förster, Jonas Graf, Jan Mares, et al.CNS Drugs|June 13, 2019
Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1Cristan A Farmer, Audrey Thurm, Nicole Farhat, et al.Pageof 211